Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression

REFERENCES

• Altucci, L., R. Addeo, L. Cicatiello, S. Dauvois, M. G. Parker, M. Truss, M. Beato, V. Sica, F. Bresciani, and A. Weisz. 1996. 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogene 12: 2315–2324.
   PubMed Web of Science ®Google Scholar
• Angus, W. G., M. Campaigne Larsen, and C. R. Jefcoate. 2000. TCDD elevates erbB2 expression and signaling in T47D cells by reversing serum potentiation of estrogen receptor activity, independent of estrogen levels and enhanced ER down-regulation. Mol. Cell. Endocrinol. 170: 1–13.
   PubMedGoogle Scholar
• Aranda, A., and A. Pascual. 2001. Nuclear hormone receptors and gene expression. Physiol. Rev. 81: 1269–1304.
   PubMed Web of Science ®Google Scholar
• Ard, P. G., C. Chatterjee, S. Kunjibettu, L. R. Adside, L. E. Gralinski, and S. B. McMahon. 2002. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol. Cell. Biol. 22: 5650–5661.
   PubMed Web of Science ®Google Scholar
• Barak, Y., and M. Oren. 1992. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J. 11: 2115–2121.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee, R. N., G. C. Banks, K. W. Trotter, H. L. Lee, and T. K. Archer. 2001. Histone H1 phosphorylation by Cdk2 selectively modulates mouse mammary tumor virus transcription through chromatin remodeling. Mol. Cell. Biol. 21: 5417–5425.
   PubMedGoogle Scholar
• Boyd, S. D., K. Y. Tsai, and T. Jacks. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2: 563–568.
   PubMed Web of Science ®Google Scholar
• Cardozo, C. P., C. Michaud, M. C. Ost, A. E. Fliss, E. Yang, C. Patterson, S. J. Hall, and A. J. Caplan. 2003. C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch. Biochem. Biophys. 410: 134–140.
   PubMed Web of Science ®Google Scholar
• Ciechanover, A., A. Orian, and A. L. Schwartz. 2000. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22: 442–451.
   PubMed Web of Science ®Google Scholar
• Connell, P., C. A. Ballinger, J. Jiang, Y. Wu, L. J. Thompson, J. Hohfeld, and C. Patterson. 2001. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3: 93–96.
   PubMed Web of Science ®Google Scholar
• Cotroneo, M. S., J. Wang, I. A. Eltoum, and C. A. Lamartiniere. 2001. Sex steroid receptor regulation by genistein in the prepubertal rat uterus. Mol. Cell. Endocrinol. 173: 135–145.
   PubMed Web of Science ®Google Scholar
• Couse, J. F., and K. S. Korach. 1999. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20: 358–417.
   PubMed Web of Science ®Google Scholar
• Dace, A., L. Zhao, K. S. Park, T. Furuno, N. Takamura, M. Nakanishi, B. L. West, J. A. Hanover, and S. Cheng. 2000. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc. Natl. Acad. Sci. USA 97: 8985–8990.
   PubMed Web of Science ®Google Scholar
• DeFranco, D. B. 2002. Navigating steroid hormone receptors through the nuclear compartment. Mol. Endocrinol. 16: 1449–1455.
   PubMed Web of Science ®Google Scholar
• Dennis, A. P., R. U. Haq, and Z. Nawaz. 2001. Importance of the regulation of nuclear receptor degradation. Front. Biosci. 6: D954–959.
   PubMed Web of Science ®Google Scholar
• Deroo, B. J., C. Rentsch, S. Sampath, J. Young, D. B. DeFranco, and T. K. Archer. 2002. Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol. Cell. Biol. 22: 4113–4123.
   PubMed Web of Science ®Google Scholar
• Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18: 7288–7293.
   PubMed Web of Science ®Google Scholar
• Fritz, W. A., J. Wang, I. E. Eltoum, and C. A. Lamartiniere. 2002. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol. Cell. Endocrinol. 186: 89–99.
   PubMed Web of Science ®Google Scholar
• Fryer, C. J., and T. K. Archer. 1998. Chromatin remodeling by the glucocorticoid receptor requires the BRG1 complex. Nature 393: 88–91.
   PubMed Web of Science ®Google Scholar
• Fryer, C. J., H. K. Kinyamu, I. Rogatsky, M. J. Garabedian, and T. K. Archer. 2000. Selective activation of the glucocorticoid receptor by steroid antagonists in human breast cancer and osteosarcoma cells. J. Biol. Chem. 275: 17771–17777.
   PubMedGoogle Scholar
• Fryer, C. J., S. K. Nordeen, and T. K. Archer. 1998. Antiprogestins mediate differential effects on glucocorticoid receptor remodeling of chromatin structure. J. Biol. Chem. 273: 1175–1183.
   PubMedGoogle Scholar
• Galigniana, M. D., P. R. Housley, D. B. DeFranco, and W. B. Pratt. 1999. Inhibition of glucocorticoid receptor nucleocytoplasmic shuttling by okadaic acid requires intact cytoskeleton. J. Biol. Chem. 274: 16222–16227.
   PubMed Web of Science ®Google Scholar
• Gallagher, J. C., S. E. Fowler, J. R. Detter, and S. S. Sherman. 2001. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J. Clin. Endocrinol. Metab. 86: 3618–3628.
   PubMed Web of Science ®Google Scholar
• Ganguli, G., J. Back, S. Sengupta, and B. Wasylyk. 2002. The p53 tumour suppressor inhibits glucocorticoid-induced proliferation of erythroid progenitors. EMBO Rep. 3: 569–574.
   PubMedGoogle Scholar
• Geyer, R. K., Z. K. Yu, and C. G. Maki. 2000. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2: 569–573.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
   PubMed Web of Science ®Google Scholar
• Hori, M., J. Shimazaki, S. Inagawa, and M. Itabashi. 2002. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res. Treat. 71: 77–83.
   Google Scholar
• Hsiao, P. W., B. J. Deroo, and T. K. Archer. 2002. Chromatin remodeling and tissue-selective responses of nuclear hormone receptors. Biochem. Cell. Biol. 80: 343–351.
   PubMedGoogle Scholar
• Htun, H., J. Barsony, I. Renyi, D. L. Gould, and G. L. Hager. 1996. Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera. Proc. Natl. Acad. Sci. USA 93: 4845–4850.
   PubMed Web of Science ®Google Scholar
• Htun, H., L. T. Holth, D. Walker, J. R. Davie, and G. L. Hager. 1999. Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. Mol. Biol. Cell. 10: 471–486.
   PubMedGoogle Scholar
• Kinyamu, H. K., C. J. Fryer, K. B. Horwitz, and T. K. Archer. 2000. The mouse mammary tumor virus promoter adopts distinct chromatin structures in human breast cancer cells with and without glucocorticoid receptor. J. Biol. Chem. 275: 20061–20068.
   PubMedGoogle Scholar
• Kraus, W. L., K. E. Weis, and B. S. Katzenellenbogen. 1995. Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol. Cell Biol. 15: 1847–1857.
   PubMed Web of Science ®Google Scholar
• Krishnan, A. V., S. Swami, and D. Feldman. 2001. Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 77: 29–37.
   PubMedGoogle Scholar
• Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299–303.
   PubMed Web of Science ®Google Scholar
• Kuiper, G. G., E. Enmark, M. Pelto-Huikko, S. Nilsson, and J. A. Gustafsson. 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93: 5925–5930.
   PubMed Web of Science ®Google Scholar
• Lange, C. A., T. Shen, and K. B. Horwitz. 2000. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl. Acad. Sci. USA 97: 1032–1037.
   PubMed Web of Science ®Google Scholar
• Lee, H. L., and T. K. Archer. 1994. Nucleosome-mediated disruption of transcription factor-chromatin initiation complexes at the mouse mammary tumor virus long terminal repeat in vivo. Mol. Cell. Biol. 14: 32–41.
   PubMedGoogle Scholar
• Lee, H. L., and T. K. Archer. 1998. Prolonged glucocorticoid exposure dephosphorylates histone H1 and inactivates the MMTV promoter. EMBO J. 17: 1454–1466.
   PubMedGoogle Scholar
• Legube, G., L. K. Linares, C. Lemercier, M. Scheffner, S. Khochbin, and D. Trouche. 2002. Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBO J. 21: 1704–1712.
   PubMed Web of Science ®Google Scholar
• Lin, H. K., L. Wang, Y. C. Hu, S. Altuwaijri, and C. Chang. 2002. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 21: 4037–4048.
   PubMed Web of Science ®Google Scholar
• Liu, G., J. A. Schwartz, and S. C. Brooks. 2000. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res. 60: 1810–1814.
   PubMed Web of Science ®Google Scholar
• Lobenhofer, E. K., L. Bennett, P. L. Cable, L. Li, P. R. Bushel, and C. A. Afshari. 2002. Regulation of DNA replication fork genes by 17beta-estradiol. Mol. Endocrinol. 16: 1215–1229.
   PubMedGoogle Scholar
• Lonard, D. M., Z. Nawaz, C. L. Smith, and B. W. O'Malley. 2000. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol. Cell 5: 939–948.
   PubMed Web of Science ®Google Scholar
• Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, et al. 1995. The nuclear receptor superfamily: the second decade. Cell 83: 835–839.
   PubMed Web of Science ®Google Scholar
• McKenna, N. J., and B. W. O'Malley. 2002. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108: 465–474.
   PubMed Web of Science ®Google Scholar
• Molinari, A. M., P. Bontempo, E. M. Schiavone, V. Tortora, M. A. Verdicchio, M. Napolitano, E. Nola, B. Moncharmont, N. Medici, V. Nigro, I. Armetta, C. Abbondanza, and G. A. Puca. 2000. Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res. 60: 2594–2597.
   PubMedGoogle Scholar
• Moll, U. M., G. Riou, and A. J. Levine. 1992. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA 89: 7262–7266.
   PubMedGoogle Scholar
• Moudgil, V. K., S. Dinda, N. Khattree, S. Jhanwar, P. Alban, and C. Hurd. 2001. Hormonal regulation of tumor suppressor proteins in breast cancer cells. J. Steroid Biochem. Mol. Biol. 76: 105–117.
   PubMed Web of Science ®Google Scholar
• Muchardt, C., and M. Yaniv. 1999. The mammalian SWI/SNF complex and the control of cell growth. Semin. Cell Dev. Biol. 10: 189–195.
   Google Scholar
• Muller, W. G., D. Walker, G. L. Hager, and J. G. McNally. 2001. Large-scale chromatin decondensation and recondensation regulated by transcription from a natural promoter. J. Cell Biol. 154: 33–48.
   PubMedGoogle Scholar
• Nawaz, Z., D. M. Lonard, A. P. Dennis, C. L. Smith, and B. W. O'Malley. 1999. Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. USA 96: 1858–1862.
   PubMed Web of Science ®Google Scholar
• Nawaz, Z., D. M. Lonard, C. L. Smith, E. Lev-Lehman, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 1999. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol. Cell. Biol. 19: 1182–1189.
   PubMed Web of Science ®Google Scholar
• Nikolaev, A. Y., M. Li, N. Puskas, J. Qin, and W. Gu. 2003. Parc: a cytoplasmic anchor for p53. Cell 112: 29–40.
   PubMed Web of Science ®Google Scholar
• Oakley, R. H., J. C. Webster, C. M. Jewell, M. Sar, and J. A. Cidlowski. 1999. Immunocytochemical analysis of the glucocorticoid receptor alpha isoform (GRalpha) using GRalpha-specific antibody. Steroids 64: 742–751.
   PubMedGoogle Scholar
• Pestell, R. G., C. Albanese, A. T. Reutens, J. E. Segall, R. J. Lee, and A. Arnold. 1999. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr. Rev. 20: 501–534.
   PubMed Web of Science ®Google Scholar
• Qin, C., T. Nguyen, J. Stewart, I. Samudio, R. Burghardt, and S. Safe. 2002. Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor kappaB/CCAAT-binding transcription factor-1 complex. Mol. Endocrinol. 16: 1793–1809.
   PubMedGoogle Scholar
• Rackoff, P. J., and C. J. Rosen. 1998. Pathogenesis and treatment of glucocorticoid-induced osteoporosis. Drugs Aging 12: 477–484.
   PubMedGoogle Scholar
• Reichardt, H. M., F. Tronche, S. Berger, C. Kellendonk, and G. Schutz. 2000. New insights into glucocorticoid and mineralocorticoid signaling: lessons from gene targeting. Adv. Pharmacol. 47: 1–21.
   PubMedGoogle Scholar
• Reyes, J. C., J. Barra, C. Muchardt, A. Camus, C. Babinet, and M. Yaniv. 1998. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J. 17: 6979–6991.
   PubMed Web of Science ®Google Scholar
• Risinger, J. I., L. A. Terry, and J. Boyd. 1994. Use of representational difference analysis for the identification of mdm2 oncogene amplification in diethylstilbestrol-induced murine uterine adenocarcinomas. Mol. Carcinog. 11: 13–18.
   PubMedGoogle Scholar
• Rogatsky, I., J. M. Trowbridge, and M. J. Garabedian. 1997. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Mol. Cell. Biol. 17: 3181–3193.
   PubMed Web of Science ®Google Scholar
• Russell, A., J. Hendley, and D. Germain. 1999. Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilization with D-type cyclins. Oncogene 18: 6454–6459.
   PubMedGoogle Scholar
• Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495–505.
   PubMed Web of Science ®Google Scholar
• Sengupta, S., J. L. Vonesch, C. Waltzinger, H. Zheng, and B. Wasylyk. 2000. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J. 19: 6051–6064.
   PubMedGoogle Scholar
• Sengupta, S., and B. Wasylyk. 2001. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev. 15: 2367–2380.
   PubMed Web of Science ®Google Scholar
• Shenoy, S. K., P. H. McDonald, T. A. Kohout, and R. J. Lefkowitz. 2001. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294: 1307–1313.
   PubMed Web of Science ®Google Scholar
• Shyr, C. R., Y. C. Hu, E. Kim, and C. Chang. 2002. Modulation of estrogen receptor-mediated transactivation by orphan receptor TR4 in MCF-7 cells. J. Biol. Chem. 277: 14622–14628.
   PubMed Web of Science ®Google Scholar
• Smith, C. L., H. Htun, R. G. Wolford, and G. L. Hager. 1997. Differential activity of progesterone and glucocorticoid receptors on mouse mammary tumor virus templates differing in chromatin structure. J. Biol. Chem. 272: 14227–14235.
   PubMedGoogle Scholar
• Sutherland, R. L., O. W. Prall, C. K. Watts, and E. A. Musgrove. 1998. Estrogen and progestin regulation of cell cycle progression. J. Mammary Gland Biol. Neoplasia 3: 63–72.
   Google Scholar
• Tao, W., and A. J. Levine. 1999. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 96: 3077–3080.
   PubMed Web of Science ®Google Scholar
• Wallace, A. D., and J. A. Cidlowski. 2001. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J. Biol. Chem. 276: 42714–42721.
   PubMed Web of Science ®Google Scholar
• Wang, X., W. Porter, V. Krishnan, T. R. Narasimhan, and S. Safe. 1993. Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated decrease of the nuclear estrogen receptor in MCF-7 human breast cancer cells. Mol. Cell. Endocrinol. 96: 159–166.
   PubMed Web of Science ®Google Scholar
• Whitesell, L., and P. Cook. 1996. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol. Endocrinol. 10: 705–712.
   PubMed Web of Science ®Google Scholar
• Wormke, M., M. Stoner, B. Saville, K. Walker, M. Abdelrahim, R. Burghardt, and S. Safe. 2003. The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol. Cell. Biol. 23: 1843–1855.
   PubMed Web of Science ®Google Scholar
• Xirodimas, D. P., C. W. Stephen, and D. P. Lane. 2001. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp. Cell Res. 270: 66–77.
   PubMedGoogle Scholar
• Yanagisawa, J., H. Kitagawa, M. Yanagida, O. Wada, S. Ogawa, M. Nakagomi, H. Oishi, Y. Yamamoto, H. Nagasawa, S. B. McMahon, M. D. Cole, L. Tora, N. Takahashi, and S. Kato. 2002. Nuclear receptor function requires a TFTC-type histone acetyl transferase complex. Mol. Cell 9: 553–562.
   PubMed Web of Science ®Google Scholar
• Yudt, M. R., and J. A. Cidlowski. 2001. Molecular identification and characterization of a and b forms of the glucocorticoid receptor. Mol. Endocrinol. 15: 1093–1103.
   PubMed Web of Science ®Google Scholar
• Zaika, A., N. Marchenko, and U. M. Moll. 1999. Cytoplasmically “sequestered” wild type p53 protein is resistant to Mdm2-mediated degradation. J. Biol. Chem. 274: 27474–27480.
   PubMedGoogle Scholar
• Zhou, F., B. Bouillard, M. O. Pharaboz-Joly, and J. Andre. 1989. Nonclassical antiestrogenic actions of dexamethasone in variant MCF-7 human breast cancer cells in culture. Mol. Cell. Endocrinol. 66: 189–197.
   PubMed Web of Science ®Google Scholar